Clinical Trials at MPTC
We are dedicated to advancing scientific knowledge about the role of proton therapy in the treatment of cancer. Clinical trials allow us to discover new and more effective treatments that would improve cancer outcomes for everyone diagnosed with the disease. With more than 30 clinical trials ongoing at our center, we are hopeful that MPTC will play a vital role in the advancement of radiation oncology.Â
Every patient treated at MPTC has access to a clinical trial. Read on to learn more about the trials we have available:Â
- GCC 1570 PCG BRE007: Phase II protocol of proton therapy for partial breast irradiation in early stage breast cancer [Sponsor: PCG] PI: Sarah McAvoy, MD
- CCTG MA.39:Â Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer [Sponsor: Canadian Cancer Trials Group] PI: Sarah McAvoy, MD
- GCC 19140: Pilot Study of Laser Interstitial Thermal Therapy Followed by Hypofractionated Radiation Therapy for Treatment of Recurrent Gliomas [Sponsor: U. Maryland] PI: Mark V. Mishra, MD
- GCC20138: Laser Interstitial Thermal Therapy Followed by Hypofractionated Radiation Therapy for Treatment of Newly Diagnoses High-Grade Gliomas [Sponsor: U. Maryland] PI: Mark V. Mishra, MD
- NRG BN009: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) For First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity ≥4 Brain Metastases/Year [Sponsor: NRG Oncology] PI: Mark V. Mishra, MD
- NRG BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases [Sponsor: NRG Oncology] PI: Mark V. Mishra, MD
- NRG CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer [Sponsor: NRG Oncology] PI: Mark V. Mishra, MD
- GCC 1886: Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine with Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer [Sponsor: University of Maryland, Baltimore] PI: Jason Molitoris, MD, PhD
- GCC 2431: A pilot study of chemoimmunotherapy combined with hyperthermia and spatially-fractionated radiotherapy in advanced biliary tract cancer  [Sponsor: University of Maryland, Baltimore] PI: Jason Molitoris, MD, PhD
- GCC 1944:Â A Randomized Phase III Trial of Two Standard Dose Fractionation Regimens for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer [Sponsor: Kara Romano, MD] PI: Sarah McAvoy, MD
- NRG HN009: Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck [Sponsor: NRG] PI: Matthew Ferris, MD
- RTOG 1216: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer [Sponsor: National Cancer Institute (NCI)] PI: Matthew Ferris, MD
- GCC 2380: A Single Arm Phase II Trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs based on Residual Circulating Tumor DNA Levels (SAVAL) Â [Sponsor: Dana-Farber Cancer Institute] PI: Jason Molitoris, MD
- S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Â [Sponsor: SWOG Cancer Research Network] PI: Matthew Ferris
- GCC 1669: Pediatric Proton Consortium Registry: Registry for pediatric patients treated with proton RTÂ [Sponsor: Massachusetts General Hospital] PI: Young Kwok, MD
- GCC 2032: Phase 1 Feasibility Study of Strength Training with Androgen Deprivation and Proton Therapy for Intermediate and High Risk Prostate Cancer [Sponsor: University of Maryland] PI: Matthew Ferris, MD
- NRG GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation [Sponsor: NRG] PI: Zaker Rana, MD
- GCC 2048:Â A Phase I Dose Escalation Study of Hypofractionated Accelerated Pelvic Nodal Radiotherapy Delivered With A Simultaneously Integrated Prostate Boost For Patients With Localized, Intermediate- And High-Risk Prostate Cancer [Sponsor: University of Maryland] PI: Mark Mishra, MD
- GCC 21136:Â Phase 2 randomized Total Eradication of metastatic lesions following definitive Radiation to the Prostate in de novo oligometaStatic prostate cancer (TERPS) trial [Sponsor: University of Maryland] PI: Phuoc Tran, MD
- NRG GU010:Â Parallel Phase III Randomized Trials Of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (Guidance)Â [Sponsor: NRG] PI: Zaker Rana, MD
- GCC 23100: A randomized trial of high-risK metachroNous oligometastatIc prostate cancer with hiGh-risk mutations witH meTastasiS directed therapy and niraparib/abiraterone acetate and prednisone (KNIGHTS) [Sponsor: University of Maryland] PI: Jason Molitoris, MD
If you’re interested in participating in a clinical trial, please call (410) 369-5351 to check on availability or speak with your physician during your consultation.Â
